$SSII SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025
https://www.globenewswire.com/news-release/20...-2025.html
FORT LAUDERDALE, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced preliminary unaudited revenue and other select operating metrics for the three and twelve months ended December 31, 2025.
For the fourth quarter of 2025, the Company expects to report:
Revenue of approximately $15.0 million, up 85% from revenue of $8.1 million in the fourth quarter of 2024.
SSi Mantra installations of 37, up 68% from 22 installations in the fourth quarter of 2024.
For the full year 2025, the Company expects to report:
Revenue of approximately $43.0 million, up 108% from revenue of $20.6 million in 2024.
SSi Mantra installations of 103, up 119% from 47 installations in 2024.
The SSi Mantra cumulative installed base totaled 168 as of December 31, 2025, up 158% from 65 as of December 31, 2024.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “We expect to report strong fourth quarter revenue growth, driven by higher unit sales of our advanced, cost-effective SSi Mantra surgical robotic system in India and abroad. We are committed to democratizing excellence in surgical care on a global scale, including in the United States and Europe. We anticipate that the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for the SSi Mantra in the first half of 2026. We also continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can obtain in the first half of 2026. We look forward to providing additional financial details when we release our fourth quarter financial results in the latter part of February.”
The Company expects to report its fourth quarter and full year 2025 financial results before the end of February.
The estimated financial and operating results in this press release are preliminary, unaudited and subject to completion, and may change as a result of management's continued review. Such preliminary results are subject to the finalization of quarter-end financial and accounting procedures. As a result, investors should exercise caution in relying on this information and should not draw any inferences from this information. This preliminary financial information should not be viewed as a substitute for full financial statements prepared in accordance with GAAP and reviewed by our independent registered public accounting firm.
https://www.globenewswire.com/news-release/20...-2025.html
FORT LAUDERDALE, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced preliminary unaudited revenue and other select operating metrics for the three and twelve months ended December 31, 2025.
For the fourth quarter of 2025, the Company expects to report:
Revenue of approximately $15.0 million, up 85% from revenue of $8.1 million in the fourth quarter of 2024.
SSi Mantra installations of 37, up 68% from 22 installations in the fourth quarter of 2024.
For the full year 2025, the Company expects to report:
Revenue of approximately $43.0 million, up 108% from revenue of $20.6 million in 2024.
SSi Mantra installations of 103, up 119% from 47 installations in 2024.
The SSi Mantra cumulative installed base totaled 168 as of December 31, 2025, up 158% from 65 as of December 31, 2024.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “We expect to report strong fourth quarter revenue growth, driven by higher unit sales of our advanced, cost-effective SSi Mantra surgical robotic system in India and abroad. We are committed to democratizing excellence in surgical care on a global scale, including in the United States and Europe. We anticipate that the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for the SSi Mantra in the first half of 2026. We also continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can obtain in the first half of 2026. We look forward to providing additional financial details when we release our fourth quarter financial results in the latter part of February.”
The Company expects to report its fourth quarter and full year 2025 financial results before the end of February.
The estimated financial and operating results in this press release are preliminary, unaudited and subject to completion, and may change as a result of management's continued review. Such preliminary results are subject to the finalization of quarter-end financial and accounting procedures. As a result, investors should exercise caution in relying on this information and should not draw any inferences from this information. This preliminary financial information should not be viewed as a substitute for full financial statements prepared in accordance with GAAP and reviewed by our independent registered public accounting firm.
